Clinical-stage biopharmaceutical company Syndax Pharmaceuticals, Inc. has received Orphan Drug Designation for axatilimab from the U.
Syndax Pharmaceuticals reported a better-than-expected loss in the fourth quarter and outpaced analysts’ expectations for revenues. Shares of the clinical-stage biopharmaceutical company dropped …
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced yesterday that the ENCORE 601 non-small cell lung cancer (NSCLC) cohort enrolling patients with disease progression on or …
It’s a very rewarding trading day for investors in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) with shares up over 50%, making the stock Wall Street’s …
